By putting these peptides on the category 2 list, it drastically restricted the type of research that could be done, says Jessica Duncan, MD, DABOM, DABA, board-certified obesity medicine physician and Chief Medical Officer at Ivim Health
The extensive safety data from clinical trials in other applications provides reassurance regarding tolerability
Research Background & Mechanistic Focus Current research use centers on GHK-Cu copper peptide signaling in follicular stem cell activation, angiogenesis pathway modulation, and dermal matrix remodeling models
The bioregulator peptide approach is fundamentally different from the larger peptides discussed earlier
Available to order in the UK, EU, USA, Canada, Australia, New Zealand, Japan, Singapore, Malaysia